Ezra Cohen, MD, is co-Director of the San Diego Center for Precision Immunotherapy and an internationally renowned translational researcher. He has been acknowledged for his contribution to the National Cancer Institute Task Force on PI3 Kinase/AKT/mTOR Targeting. A physician-scientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to targeted therapy. His recent National Institutes of Health-funded work in the study of epidermal growth factor receptor inhibitors in head and neck cancer has contributed to the understanding of the biology of this critical signaling network, integration of these agents into standard of care, and definition of
mechanisms to overcome resistance. He was recently appointed as chair of the NCI Head and Neck Cancer Steering Committee that oversees NCI-funded clinical research (including all NCI Cooperative Group trials) in this disease. Dr. Cohen is Associate Director for Translational Science and team leader in Solid Tumor Therapeutics research program. He brings his expertise and preeminent reputation in head and neck cancer research and patient care to solid tumor therapeutics. Among other roles, he is co-leader of the C3 steering committee, chair of the Protocol Review and MonitoringCommittee (PRMC) and serves as a member of the Cancer Council, and the cancer center’s Executive Committee. Dr. Cohen recently served as editor-in-chief of Oral Oncology, the highest impact specialty journal in head and neck cancer, and has recently chaired two Multidisciplinary Head and Neck Cancer Symposia—the largest international meeting of its kind—sponsored by the American Society for Radiation Oncology, the American Society of Clinical Oncology and the American Head and Neck Society. He has been the principal investigator on multiple studies of novel agents in head and neck cancer and other solid tumors in all phases of development including chemoprevention, phase I, II, and III trials. Dr. Cohen has authored more than 120 papers and has presented his research at national and international meetings. In addition, he is Chair of the Career Development Subcommittee of the American Society of Clinical Oncology and has served as a grant reviewer for the NIH, American Association for Cancer Research, American Society of Clinical Oncology, and the Ontario Institute for Cancer Research.